Medical Devices

With a year of record growth and major acquisitions, all eyes are on AHR's Q4 results to see if its strong momentum will carry into 2026.

A landmark trial reveals a new drug combination from BeOne Medicines extends life significantly in advanced stomach cancer, poised to become the new standard.

A new national scholarship from a Las Vegas physician looks beyond grades, using essays to find future doctors committed to ethical service and community care.

A promising antiviral combination for Long COVID gets a major boost, accelerating its path to a pivotal clinical trial led by top researchers.

A new alliance between Medtech Incubator and Leap Distributors promises to bridge the gap between device development and patient access in the U.S.

With its rare disease drug JURVIGO® in late-stage trials, Mezzion appoints a veteran leader to navigate the path to approval and commercialization.

The newly merged Medispend aims to dominate the compliance software market with an expanded suite, deep financial backing, and a string of strategic buys.

With major clinical trials, including a novel approach for Alzheimer's, and key market access wins, MMI's Symani system is poised to redefine microsurgery.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.

STAAR Surgical stockholders rejected a lucrative Alcon merger, betting on the standalone potential of their EVO ICL lenses despite recent financial headwinds.

With its first drug for a rare disease now on the market, Stealth BioTherapeutics bets its future on a deep pipeline targeting mitochondrial dysfunction.

In a strategic move to become a one-stop shop for medical implants, Resonetics acquires pulse generator tech, targeting the booming neuromodulation and BCI markets.

Health Canada greenlights an 8-week pill for acute HCV, a move experts say is a game-changer in the race to eradicate the virus by 2030.

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.

Cosmos Health's subsidiary will manufacture the advanced generic pain reliever PathMuscle, securing a major contract and enhancing its European footprint.

Inspira Technologies announces a landmark deal to acquire a liquid biopsy firm, securing a $15M investment at a $180M valuation to enter the cancer market.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

With blockbuster sales from VYJUVEK, Krystal Biotech heads to J.P. Morgan with investors eager for news on its global growth and ambitious pipeline.